### [Murray et al. Page 1499][1] In this First Disclosure, Murray and colleagues describe TPX-0131, a compact macrocyclic ALK inhibitor designed to fit completely in the ATP-binding pocket and inhibit both wild-typ. ALK and drug-resistance mutations. Using a combination of biochemical, cellular,

中文翻译：

---

本期文章精选

### [默里等人。第 1499 页][1] 在首次披露中，Murray 及其同事描述了 TPX-0131，这是一种紧凑型大环 ALK 抑制剂，旨在完全适合 ATP 结合口袋并抑制两种野生型。ALK 和耐药突变。结合生化、细胞、